Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack A Roth

Showing results (11-20 of 352) with videos related to

Pageof 36
Sort By:
Thoracic Surgery Clinics|July 14, 2007
Stereotactic body radiation therapy for stage I non-small cell lung cancerJoe Y Chang, Jack A Roth
Critical Reviews in Oncogenesis|August 3, 2016
Gene Therapy for Lung CancerHumberto Lara-Guerra, Jack A Roth
Surgical Oncology Clinics of North America|December 19, 2002
Clinical update of Ad-p53 gene therapy for lung cancerStephen G Swisher, Jack A Roth
Oncology (Williston Park, N.Y.)|January 11, 2012
Thoracic metastases from sarcoma: a commentaryShanda H Blackmon, Jack A Roth
Methods in Molecular Biology (Clifton, N.J.)|November 16, 2011
High throughput profiling of serum phosphoproteins/peptides using the SELDI-TOF-MS platformLin Ji, Gitanjali Jayachandran, Jack A Roth
Methods in Molecular Biology (Clifton, N.J.)|November 16, 2011
Analysis of protein-protein interaction using proteinchip array-based SELDI-TOF mass spectrometryGitanjali Jayachandran, Jack A Roth, Lin Ji
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Current status of gene therapy for lung cancer and head and neck cancerChulso Moon, Yun Oh, Jack A Roth
Cancer Biology & Therapy|December 2, 2009
RNAi-induced synthetic lethality in cancer therapyBingbing Dai, Bingliang Fang, Jack A Roth
Oncogene|April 24, 2002
Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cellsSeiichi Nakamura, Jack A Roth, Tapas Mukhopadhyay
Clinical Lung Cancer|March 18, 2009
Neoadjuvant and intrapleural therapies for malignant pleural mesotheliomaAnne S Tsao, Reza Mehran, Jack A Roth
Pageof 36

Showing results (11-20 of 352) with videos related to

Sort By:
Pageof 36
Thoracic Surgery Clinics|July 14, 2007
Stereotactic body radiation therapy for stage I non-small cell lung cancerJoe Y Chang, Jack A Roth
Critical Reviews in Oncogenesis|August 3, 2016
Gene Therapy for Lung CancerHumberto Lara-Guerra, Jack A Roth
Surgical Oncology Clinics of North America|December 19, 2002
Clinical update of Ad-p53 gene therapy for lung cancerStephen G Swisher, Jack A Roth
Oncology (Williston Park, N.Y.)|January 11, 2012
Thoracic metastases from sarcoma: a commentaryShanda H Blackmon, Jack A Roth
Methods in Molecular Biology (Clifton, N.J.)|November 16, 2011
High throughput profiling of serum phosphoproteins/peptides using the SELDI-TOF-MS platformLin Ji, Gitanjali Jayachandran, Jack A Roth
Methods in Molecular Biology (Clifton, N.J.)|November 16, 2011
Analysis of protein-protein interaction using proteinchip array-based SELDI-TOF mass spectrometryGitanjali Jayachandran, Jack A Roth, Lin Ji
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Current status of gene therapy for lung cancer and head and neck cancerChulso Moon, Yun Oh, Jack A Roth
Cancer Biology & Therapy|December 2, 2009
RNAi-induced synthetic lethality in cancer therapyBingbing Dai, Bingliang Fang, Jack A Roth
Oncogene|April 24, 2002
Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cellsSeiichi Nakamura, Jack A Roth, Tapas Mukhopadhyay
Clinical Lung Cancer|March 18, 2009
Neoadjuvant and intrapleural therapies for malignant pleural mesotheliomaAnne S Tsao, Reza Mehran, Jack A Roth
Pageof 36